These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25789864)

  • 1. Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis.
    Ferrín G; Rodríguez-Perálvarez M; Aguilar-Melero P; Ranchal I; Llamoza C; Linares CI; González-Rubio S; Muntané J; Briceño J; López-Cillero P; Montero-Álvarez JL; de la Mata M
    PLoS One; 2015; 10(3):e0118527. PubMed ID: 25789864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE.
    Ferrín G; Ranchal I; Llamoza C; Rodríguez-Perálvarez ML; Romero-Ruiz A; Aguilar-Melero P; López-Cillero P; Briceño J; Muntané J; Montero-Álvarez JL; De la Mata M
    Liver Int; 2014 Mar; 34(3):438-46. PubMed ID: 23944848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
    Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
    PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of hepatitis C virus infection on circulating levels of sICAM-1 and VEGF in patients with hepatitis C and hepatocellular carcinoma (HCC) and their role in enhancing detection of HCC.
    Helaly GF; Abou Shamaa LA
    Egypt J Immunol; 2006; 13(1):27-38. PubMed ID: 17974148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.
    Mustafa MG; Petersen JR; Ju H; Cicalese L; Snyder N; Haidacher SJ; Denner L; Elferink C
    Mol Cell Proteomics; 2013 Dec; 12(12):3640-52. PubMed ID: 24008390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma.
    Rashad NM; El-Shal AS; Shalaby SM; Mohamed SY
    Mol Cell Biochem; 2018 Oct; 447(1-2):125-136. PubMed ID: 29455432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies.
    Zhu J; Lin Z; Wu J; Yin H; Dai J; Feng Z; Marrero J; Lubman DM
    J Proteome Res; 2014 Jun; 13(6):2986-97. PubMed ID: 24807840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum anti-Ku86: a potential biomarker for early detection of hepatocellular carcinoma].
    Chu L; Zhang X; Wang G; Zhou W; Du Z; Liu A; Zhao H
    Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):123-7. PubMed ID: 24796461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
    Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
    Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum fucosylated paraoxonase 1 as a potential glycobiomarker for clinical diagnosis of early hepatocellular carcinoma using ELISA Index.
    Zhang S; Jiang K; Zhang Q; Guo K; Liu Y
    Glycoconj J; 2015 May; 32(3-4):119-25. PubMed ID: 25702281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a serum microRNA panel as biomarkers for early diagnosis of hepatocellular carcinoma post-hepatitis C infection in Egyptian patients.
    Elemeery MN; Badr AN; Mohamed MA; Ghareeb DA
    World J Gastroenterol; 2017 Jun; 23(21):3864-3875. PubMed ID: 28638226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma.
    Oksuz Z; Serin MS; Kaplan E; Dogen A; Tezcan S; Aslan G; Emekdas G; Sezgin O; Altintas E; Tiftik EN
    Mol Biol Rep; 2015 Mar; 42(3):713-20. PubMed ID: 25391771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased serum reverse triiodothyronine levels at diagnosis of hepatocellular carcinoma in patients with compensated HCV-related liver cirrhosis.
    Sorvillo F; Mazziotti G; Carbone A; Morisco F; Cioffi M; Rotondi M; Stornaiuolo G; Amato G; Gaeta GB; Caporaso N; Carella C
    Clin Endocrinol (Oxf); 2003 Feb; 58(2):207-12. PubMed ID: 12580937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein.
    Iacovazzi PA; Trisolini A; Barletta D; Elba S; Manghisi OG; Correale M
    Clin Chem Lab Med; 2001 Oct; 39(10):961-5. PubMed ID: 11758611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of hepatocellular carcinoma in hepatitis C patients: biomarker discovery by LC-MS.
    Bowers J; Hughes E; Skill N; Maluccio M; Raftery D
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 966():154-62. PubMed ID: 24666728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAGE-4 gene m-RNA and TGF in blood as potential biochemical markers for HCC in HCV-infected patients.
    Hussein YM; Morad FE; Gameel MA; Emam WA; El Sawy WH; El Tarhouny SA; Bayomy ES; Raafat N
    Med Oncol; 2012 Dec; 29(5):3055-62. PubMed ID: 22653756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Cytokine of IL-10 and IL-12 in Chronic Liver Disease: The Immune and Inflammatory Response.
    El-Emshaty HM; Nasif WA; Mohamed IE
    Dis Markers; 2015; 2015():707254. PubMed ID: 26783377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis.
    Ulu M; Alacacioglu A; Yuksel E; Pamukk BO; Bozkaya G; Ari A; Yuksel A; Sop G; Alacacioglu I
    Saudi J Gastroenterol; 2015; 21(1):47-50. PubMed ID: 25672239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
    Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India.
    Kumar M; Kumar R; Hissar SS; Saraswat MK; Sharma BC; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2007 Jul; 22(7):1104-11. PubMed ID: 17559381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.